These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38028545)

  • 1. High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers.
    Ma J; Chen K; Ding Y; Li X; Tang Q; Jin B; Luo RY; Thyparambil S; Han Z; Chou CJ; Zhou A; Schilling J; Lin Z; Ma Y; Li Q; Zhang M; Sylvester KG; Nagpal S; McElhinney DB; Ling XB; Chen B
    Front Mol Biosci; 2023; 10():1257079. PubMed ID: 38028545
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors.
    Ma J; Lin Z; Zhang Y; Ding Y; Tang Q; Qian Y; Jin B; Luo RY; Liao WL; Thyparambil S; Han Z; Chou CJ; Schilling J; Li Q; Zhang M; Lin Y; Ma Y; Sylvester KG; Nagpal S; McElhinney DB; Ling XB; Chen B
    Front Immunol; 2024; 15():1343109. PubMed ID: 39144147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid-based metabolomics to characterize different types of brain tumors.
    Wang FX; Chen K; Huang FQ; Alolga RN; Ma J; Wu ZX; Fan Y; Ma G; Guan M
    J Neurol; 2020 Apr; 267(4):984-993. PubMed ID: 31822990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment.
    Zhou L; Li Q; Xu J; Wang S; Song Z; Chen X; Ma Y; Lin Z; Chen B; Huang H
    Neurooncol Adv; 2023; 5(1):vdac181. PubMed ID: 36879663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Logistic regression modeling of cytokines for cerebrospinal fluid evaluation in primary central nervous system lymphoma.
    Wang D; Wu Y; Ma J; Xu Z; Tao H; Guan Y; Wang J; Chen K; Chen B; Xie J; Jiang H; Guan M
    Clin Chim Acta; 2024 Aug; 562():119879. PubMed ID: 39029646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoproteome analysis of cerebrospinal fluid extracellular vesicles in primary central nervous system lymphoma.
    Deng Y; Li Q; Sun J; Ma L; Ding Y; Cai Y; Iliuk A; Chen B; Xie Z; Tao WA
    Analyst; 2023 Jul; 148(15):3594-3602. PubMed ID: 37403840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry.
    Waldera-Lupa DM; Poschmann G; Kirchgaessler N; Etemad-Parishanzadeh O; Baberg F; Brocksieper M; Seidel S; Kowalski T; Brunn A; Haghikia A; Gold R; Stefanski A; Deckert M; Schlegel U; Stühler K
    Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32610669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma.
    Shao J; Chen K; Li Q; Ma J; Ma Y; Lin Z; Kang H; Chen B
    Cancer Manag Res; 2020; 12():6261-6268. PubMed ID: 32801871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
    Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
    Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas.
    Zajdel M; Rymkiewicz G; Sromek M; Cieslikowska M; Swoboda P; Kulinczak M; Goryca K; Bystydzienski Z; Blachnio K; Ostrowska B; Borysiuk A; Druzd-Sitek A; Walewski J; Chechlinska M; Siwicki JK
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
    Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
    Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    Hottenrott T; Schorb E; Fritsch K; Dersch R; Berger B; Huzly D; Rauer S; Tebartz van Elst L; Endres D; Stich O
    J Neurol; 2018 May; 265(5):1106-1114. PubMed ID: 29511863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex vivo NMR metabolomics approach using cerebrospinal fluid for the diagnosis of primary CNS lymphoma: Correlation with MR imaging characteristics.
    Kim JH; An YJ; Kim TM; Kim JE; Park S; Choi SH
    Cancer Med; 2023 Feb; 12(4):4679-4689. PubMed ID: 35941814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma.
    Hu Y; Zhang Q; Wu Z; Chen K; Xu X; Ma W; Chen B; Jin L; Guan M
    Discov Oncol; 2023 Nov; 14(1):205. PubMed ID: 37971595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma.
    Cheng CL; Yao CY; Huang PH; Yu CW; Fang WQ; Chuang WH; Wu SJ; Lin YJ; Hung YC; Tsai CH; Yu SC; Chou WC; Tien HF
    Br J Haematol; 2023 Apr; 201(1):75-85. PubMed ID: 36480431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
    Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
    Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.